What Blood Work Actually Matters on a Peptide Protocol?

There are two common failure modes in peptide lab monitoring, and they sit at opposite ends of the same problem. The first is running no bloodwork at all, on the reasoning that a compound sold as research grade does not arrive with a monitoring schedule attached. The second is ordering a sprawling forty marker panel, watching every value drift a few points, and having no framework for deciding which of those drifts actually means something.

The useful middle is narrower than most people expect, because for any given peptide class there are usually two or three markers that carry real signal, a handful of safety labs that catch the rare problem, and a long list of tests that move around without telling you anything you can act on.

This article covers which biomarkers the trial literature and FDA prescribing information actually track for growth hormone axis peptides and GLP-1 receptor agonists, how far those markers moved, when to draw them, and why the peptides with the loudest online reputations come with the least useful monitoring. It is educational content about published research rather than medical advice or a recommendation to use any compound.

The marker that matters is IGF-1 rather than growth hormone itself, and that distinction is the most important practical one in the category while also being the one most routinely gotten wrong.

Growth hormone is released in pulses roughly every three to five hours in adults, with the largest burst arriving in early slow wave sleep, and between those pulses serum levels can fall close to undetectable. A single random growth hormone draw therefore reports whether the needle happened to arrive during a burst rather than anything about total secretion.

IGF-1 is the downstream product of that secretion, produced by the liver in response to growth hormone exposure and circulating bound to IGFBP-3 and the acid labile subunit, which gives it a half life measured in hours rather than minutes. The practical result is that IGF-1 integrates growth hormone activity across roughly a full day into one stable number, with no fasting required and no meaningful sensitivity to the time of day.

One testing caveat deserves more attention than it usually gets, because high dose biotin supplementation interferes with a wide range of immunoassays and the standard guidance is to stop biotin 72 hours before the draw. Someone taking a routine hair and nails supplement can generate a genuinely wrong IGF-1 result and have no particular reason to suspect it.

The target is an age adjusted standard deviation score somewhere between minus 2 and plus 2, which is simply the normal range expressed in standard deviations rather than in raw units.

Raw IGF-1 in ng/mL means very little without an age reference, because IGF-1 falls steadily across adult life and a value of 200 ng/mL is unremarkable at 25 while sitting at the top of normal at 60. Converting to a standard deviation score, sometimes called a z score, standardizes the result against the age and sex matched population mean, which is how the clinical literature reports it. International guidance for adult growth hormone deficiency replacement recommends adjusting dose on clinical response, side effects and serum IGF-1 SDS, keeping that score inside the normal range and remeasuring every 6 to 12 months once maintenance dosing is established.

Where someone sits within that range matters as well. Comparative work on low normal versus high normal targeting found that pushing IGF-1 SDS into the upper band of 1 to 2 produced better outcomes in body fat composition, waist circumference and microcirculatory function, though at the cost of increased insulin resistance and myalgias, while targeting the lower band was more often associated with fatigue. There is no free position anywhere on that curve.

The clearest published stopping rule comes from tesamorelin, whose prescribing information directs prescribers to monitor IGF-1 during therapy and consider discontinuation on persistent elevation, giving greater than 3 SDS as the worked example, particularly where the efficacy response is not robust. That is a concrete number in a field that mostly declines to offer them.

Glucose matters because growth hormone acts as a counter regulatory hormone to insulin, so raising it reliably degrades insulin sensitivity, and this is expected pharmacology rather than a rare idiosyncratic reaction.

The cleanest long duration dataset comes from Nass and colleagues, who ran a two year double blind randomized trial of the oral growth hormone secretagogue MK-677 in healthy older adults and published it in Annals of Internal Medicine in 2008. IGF-1 climbed 55 percent at two weeks and 88 percent by four weeks on 25 mg, restoring levels to those typical of young adults, while fasting glucose rose roughly 5 mg/dL and insulin sensitivity decreased measurably, with average fasting glucose in that arm moving from approximately 95 to 105 mg/dL across the two years.

Tesamorelin produces the same signal inside a regulated trial setting. Mean baseline HbA1c was 5.3 percent in both arms, and the proportion who went on to meet the diabetes threshold of HbA1c at or above 6.5 percent was 5 percent on tesamorelin against 1 percent on placebo, a hazard ratio of 3.3. The label accordingly instructs prescribers to evaluate glucose status before initiating and to monitor all treated patients periodically for impaired glucose tolerance or diabetes.

The practical implication is that a growth hormone axis protocol showing a rising IGF-1 alongside a rising fasting glucose is not a protocol working partially, since it is doing precisely what the pharmacology predicts in both directions at once, and the glucose number is the one that decides whether the trade is worth accepting.

Three tests carry most of the weight before a GLP-1 receptor agonist, namely HbA1c, a comprehensive metabolic panel and TSH, with a lipid panel and complete blood count commonly added and prescribers typically wanting results from within the previous six months.

Each of those three answers a distinct question. HbA1c establishes the glycemic starting position the entire therapy will be measured against, sorting someone into the diabetic, prediabetic or normoglycemic band. The comprehensive metabolic panel covers renal function through creatinine and eGFR alongside hepatic enzymes and electrolytes, which matters because the dominant adverse event profile of these compounds is gastrointestinal and sustained vomiting or diarrhea produces volume depletion and acute kidney injury. TSH addresses the thyroid question raised by the boxed warning on thyroid C cell tumors, carrying most weight in anyone with known nodular thyroid disease.

The typical follow up cadence in practice is a repeat panel every three to six months, weighted toward the earlier end during dose escalation, which is when gastrointestinal adverse events and the volume loss that follows them are most likely to appear.

Calcitonin and routine pancreatic enzymes are the two clearest examples of tests that get ordered often and inform decisions rarely.

The semaglutide prescribing information is unusually direct about calcitonin, stating that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of medullary thyroid carcinoma, and that it may increase the risk of unnecessary procedures given low test specificity and a high background incidence of thyroid disease. The label does note that a significantly elevated calcitonin warrants further evaluation and that medullary thyroid carcinoma patients usually show values above 50 ng/L, so the position is not that the number is meaningless but that screening an asymptomatic population with it generates more harm through downstream procedures than it prevents.

Pancreatic enzymes occupy a similar place. Lipase elevation greater than three times the upper limit of normal occurred in 4.7 percent of semaglutide treated patients against 1.3 percent on placebo, and the label describes the significance of lipase or amylase elevation as unknown without other signs and symptoms of pancreatitis, which leaves an isolated high lipase in someone who feels well as a common finding with no clear action attached to it.

The third category of noise covers the monitoring conversation around the repair and healing peptides, because BPC-157, TB-500 and their relatives have no established human pharmacodynamic biomarker at all. There is no serum marker reflecting target engagement, no published human dose response curve to anchor a number against and no trial derived safety panel, so anyone presenting a lab protocol for these compounds is extrapolating from general safety chemistry, which catches gross organ dysfunction and nothing more specific.

Consistency matters more than any specific timing rule, because a good deal of what people read as a treatment effect turns out on inspection to be measurement variance.

IGF-1 is the forgiving case here, since it requires no fasting and stays stable enough across the day that a single morning sample is reliable. The variable worth controlling is position within the dosing interval, particularly for long acting compounds where concentration is not flat across the week, so drawing at the same point in the cycle every time removes a source of drift that has nothing to do with the protocol.

Fasting glucose, insulin and lipids are the unforgiving case, because these are genuinely fasting dependent and comparing a fasted baseline against a follow up that was not fasted produces changes that look like drug effects while being nothing of the kind.

Two practical rules cover most of the remaining ground. Use the same laboratory and the same assay across a series, because IGF-1 in particular varies between assay platforms enough to matter once the result is converted into a standard deviation score. Take a real baseline before starting rather than three weeks in, because a first draw taken mid protocol leaves you comparing yourself against a population reference range instead of against yourself.

The monitoring picture across peptide classes is considerably more asymmetric than the marketing around it suggests. Growth hormone axis compounds come with a genuinely informative biomarker in IGF-1, a published target range expressed in standard deviations, one concrete stopping threshold written into the tesamorelin label, and a well characterized metabolic cost visible in fasting glucose and HbA1c, which together amount to a monitoring framework you can actually work from.

GLP-1 receptor agonists come with a sensible baseline panel focused on glycemic status and organ function, a clear follow up cadence, and an unusually explicit label position that two of the most commonly ordered tests in the category should not be used as routine screens.

The repair and healing peptides come with none of this, and that absence is itself the finding, worth sitting with rather than filling in with a panel that looks thorough while answering nothing. None of this replaces medical supervision, since most research peptides are not approved for human use and the ones that are belong with a clinician who knows your history and can read a number in the context of everything else going on.